Jazz Pharmaceuticals (JAZZ) Q3 2026 earnings review
Jazz raises its sales plan, but a buyout erases profit
Jazz Pharmaceuticals, a maker of rare sleep, epilepsy and cancer medicines, grew sales while an acquisition charge wiped out profit. Third-quarter revenue rose 10% from a year ago to $1.24 billion as its sleep drug Xywav added 425 patients and cancer treatments expanded. Chief executive Renee Gala lifted the full-year sales plan, which by our math points to about 8% growth in the fourth quarter.
| Revenue excluding Modeyso | +6% headline revenue: $1,243M (+10.4% from a year ago) |
|---|---|
| Xywav sleep drug sales | $482.8M +12% from a year ago (425 net patients added) |
| Loss per share, excluding one-offs | -$3.88 includes $11.03 per share Actio research charge |
| Full-year revenue outlook | Raised $138M middle of the range: $4.81B (+12.8% growth) |
⚖️ Verdict: 🟢 Bullish
The story got better because the feared second-half price drop on Xywav did not show up and the stomach cancer launch of Ziihera started on time. By our math, Xywav revenue per patient held steady from a year ago, proving the earlier second-half plan was cautious. One caution: Jazz paid for the Actio acquisition with a $754 million research write-off and issued $1.25 billion in exchangeable debt, while epilepsy drug Epidiolex shrank 2%.
The question now is whether Ziihera and lung-cancer drug Zepzelca can keep total growth near 10% as last year's cancer launches pass their anniversaries and trim gross margin. Either community doctors turn early Ziihera orders into repeat prescriptions, or rising cancer royalties and uneven Epidiolex sales compress profit growth. Fourth-quarter Ziihera sales and initial clinical data from the Actio epilepsy drug will tell.
🐂 Bull Case
Xywav Kept Growing and Drove a Higher Plan
Xywav, a low-sodium sleep medicine for narcolepsy and idiopathic hypersomnia, brings in nearly two-fifths of revenue. Investors worried that cheaper high-sodium copycat drugs and insurance hurdles would cut Xywav prices in the second half. Instead, Jazz Pharmaceuticals cited "differentiated benefits of low-sodium Xywav" as the medicine grew 11.9% from a year ago to $482.8 million.
- Active Xywav patients: 17,550, up 12.0% from a year ago after 425 net additions
- Revenue per average active patient: flat (-0.2% from a year ago) by our math
- Implied fourth-quarter company revenue growth: 4.8% to 11.0% by our math, up from flat to 6% in the prior second-half plan
That steady revenue per patient matters because the earlier full-year outlook left room for a 6% price drop in the second half. Chief executive Renee Gala lifted the full-year revenue forecast by $137.5 million at the middle of the range, proving the prior plan was cautious. One quarter does not erase the risk of future insurance pushback or generic entry in 2028.
What to watch: fourth-quarter Xywav net patient additions and revenue per average patient in the full-year report. A drop in revenue per patient below $28,000 in the fourth quarter would show insurance rebates are starting to bite.
Ziihera Won Approval and Community Doctors Ordered Early
Ziihera is an antibody drug initially approved for bile-duct cancer that Jazz wants to turn into a major cancer treatment. On August 25, US regulators approved Ziihera for first-line stomach and esophageal cancer (GEA), a much larger patient group. In its first full month on the market, average daily demand vials rose about 40%, lifting third-quarter Ziihera sales to $20.6 million from $15.4 million last quarter.
The drugmaker reported "a threefold increase in new ordering accounts, 80% of which are community based" and won preferred status in US national cancer treatment guidelines. Final three-year trial data also showed patients on the three-drug Ziihera combination lived a median of 27 months, with nearly 40% alive at three years. That survival proof and community uptake give the launch early momentum.
What to watch: fourth-quarter Ziihera net sales in the first full quarter of the stomach cancer launch. A reading above $30 million would confirm that community clinic orders are turning into repeat prescriptions.
First-Line Lung Cancer Carried Oncology as Modeyso Lapped
Jazz's cancer division grew 34.5% from a year ago to $387.1 million, making up 31.1% of total revenue. Critics noted that more than half of second-quarter cancer growth came from Modeyso, a brain-tumor drug acquired last year. Now that Modeyso is passing its August 2025 launch anniversary, underlying cancer sales excluding Modeyso still grew 17.8% from a year ago by our math.
Zepzelca, a lung-cancer drug, rose 31.7% to $104.4 million on strong adoption in first-line maintenance therapy, even as the FDA approved a label update "removing the second-line indication" on September 30. Modeyso sales reached $61.1 million with about 725 cumulative patients treated, adding roughly 125 patients this quarter versus 100 in the second quarter. Separately, US regulators set an April 16, 2027 review date for a new capsule version of epilepsy drug Epidiolex.
What to watch: first-half 2027 overall survival results from the Phase 3 ACTION trial for Modeyso. A positive readout is required to convert Modeyso's conditional approval into a full first-line label.
🐻 Bear Case
The Actio Deal Wiped Out Profit and Raised Debt
"Our third-quarter performance reflects sustained execution across the business and gives us confidence to raise our full-year total revenue guidance," chief executive Renee Gala said. While Jazz treats business development as a growth driver, its September purchase of Actio Biosciences triggered a $754.2 million research write-off that pushed third-quarter profit excluding one-offs to a loss of $3.88 per share.
- Actio research charge: $754.2 million, or $11.03 per share excluding one-offs
- Profit per share excluding one-offs and Actio: $7.15 by our math, down from $7.93 a year ago after stripping out prior-year tax and legal one-offs
- Carrying net debt: $2.71 billion, up $561.4 million from the second quarter by our math after issuing $1.25 billion of 2032 exchangeable notes
The company bought back $225 million of shares alongside the bond issue and approved a new $500 million buyback plan in October. Yet Actio's epilepsy drug ABS-1230 is only in an early Phase 1b/2a trial, even though it "demonstrated meaningful seizure reductions in an early clinical proof-of-concept trial in children with KCNT1 epilepsy". Paying three-quarters of a billion dollars for an early-stage asset tests deal discipline.
What to watch: initial patient data for ABS-1230 (now JZP6979) at a medical meeting in the fourth quarter of 2026. Weak seizure reduction or safety issues would show Jazz overpaid.
Epidiolex Sales Fell and Cancer Royalties Trimmed Margin
Epidiolex, Jazz's cannabis-based medicine for severe epilepsy and its second-largest product, saw sales fall 2.4% from a year ago to $295.4 million after growing 16% in the second quarter. The biopharma group blamed "lower U.S. gross-to-net deductions in 3Q25 and lower levels of inventory build in 3Q26 due to wholesaler buying patterns". Older leukemia drug Vyxeos also shrank 9.6% to $34.0 million, while Rylaze grew 6.4% to $106.3 million.
At the same time, gross margin excluding one-offs fell 1.1 percentage points from a year ago to 91.5%. Cost of product sales excluding one-offs — the cost of making the medicines and paying royalties — rose 1.1 percentage points to 8.5% of revenue because Modeyso and Zepzelca carry higher royalty bills than sleep drugs. On a reported basis, gross margin rose 2.5 percentage points to 91.1% only because an acquisition inventory charge ended in the second quarter.
What to watch: fourth-quarter Epidiolex sales and gross margin excluding one-offs, where the full-year plan implies about 88.9% in the fourth quarter by our math. Another drop in Epidiolex sales would show demand is slowing beyond rebate timing.
Risks This Quarter Didn't Answer
Five standing concerns from prior quarters received no new details in the third-quarter earnings release because the call transcript and quarterly filing are not yet available.
- Rival sleep drugs (orexin-2 agonists): management's defense of Xywav against upcoming competitors awaits the conference call Q&A.
- Authorized generic oxybate contract: Hikma's right to give termination notice opened on October 1, 2026; the quarterly filing will show if notice was given.
- Zepzelca generic lawsuits: status of patent litigation against Qilu and other generic filers awaits the quarterly filing's legal footnote.
- US drug-pricing rules: exposure of Rylaze and Epidiolex to Medicaid rebate changes and government price rules got no update.
- Manufacturing tariffs: potential duties on medicines made in Ireland, the UK and Italy were not mentioned in the release.
👓 Other Themes
Jazz Cut Loan Rates and Booked Restructuring Costs
Jazz recorded $34.2 million of restructuring and other costs inside selling, general and administrative expenses this quarter, without stating a headcount or savings target in the release. Separately, the Dublin-based company amended its Term Loan B to cut the interest margin by 0.5 percentage points and extend the maturity by five years to May 2033, which it expects will save cash interest.
💲 Other KPIs
Cash generated from operations reached $1.33 billion in the first nine months, up 33.9% from a year ago. By our math, subtracting first-half cash flow leaves $506.1 million for the third quarter, up 6.6% from a year ago after a 58.9% jump in the first half. Capital spending was not disclosed in the release.
Unpaid bills to suppliers nearly tripled from $128.5 million in the second quarter and rose 211.5% from $122.1 million at the end of 2025. That jump helped lift third-quarter operating cash flow, while customer receivables dipped slightly to $873.7 million from $880.9 million last quarter.
Weighted-average diluted shares fell from 69.4 million in the second quarter to 64.7 million, up 5.0% from 61.6 million a year ago. Because the Actio charge caused a net loss, accounting rules excluded dilutive stock options and exchangeable notes from the third-quarter count; the nine-month diluted count was 68.6 million.
🔮 Guidance
Raised. The middle of the range moved up $137.5 million to $4,812.5 million, or 12.8% growth for the year. By our math, that leaves $1,254.8–1,329.8 million for the fourth quarter, or 4.8% to 11.0% growth (7.9% at the middle) compared with 10.4% in the third quarter. This is the second raise this year after a $300 million lift in August.
Raised. Jazz lifted its full-year gross margin plan excluding one-offs by 0.5 percentage points after running at 91.8% through the first nine months. By our math, the 91.0% middle of the full-year range implies fourth-quarter gross margin excluding one-offs will dip to about 88.9% as royalty-bearing cancer drugs grow. Reported gross margin outlook was held at 89–90%.
Unchanged. The full-year plan for selling, general and administrative costs excluding one-offs stays at $1,350 million at the middle of the range. After spending $979.7 million in the first nine months ($328.0 million in the third quarter), the outlook leaves $370.3 million for the fourth quarter by our math.
Raised. Reported selling, general and administrative expense outlook moved up by $39.5 million at the middle of the range to $1,570.5 million. The drugmaker raised the range to include the $34.2 million of restructuring costs recorded in the third quarter. By our math, that leaves $420.7 million for the fourth quarter.
Unchanged. Research and development spending excluding one-offs remains planned at $750 million at the middle of the range, where it has sat all year. With $546.1 million spent in the first nine months ($188.9 million in the third quarter), the plan leaves $203.9 million for the fourth quarter by our math.
Raised. Reported research and development outlook ticked up $2 million at the middle of the range to $847.5 million. Acquired research write-offs like the $754.2 million Actio charge are reported on a separate line and excluded from this figure. By our math, the outlook leaves $232.1 million for the fourth quarter.
Raised. The full-year tax rate outlook excluding one-offs jumped 8 percentage points at the middle of the range to 20.5%, while the reported tax rate plan rose from 0–10% to 20–30%. Jazz said the increase comes from the $754.2 million Actio research charge, which reduces pre-tax profit without creating a matching tax deduction.
Unchanged. Management kept the full-year diluted share count forecast at 69.5 million at the middle of the range, despite buying back $225 million of stock in the third quarter. Because the nine-month average is 68.6 million, hitting the full-year midpoint implies about 72.2 million diluted shares in a profitable fourth quarter by our math.
❓ Key Questions
Why were franchise outlooks for sleep and Xywav omitted?
Last quarter Jazz guided to $2.025–2.125 billion in rare sleep revenue and double-digit Xywav growth for 2026. The third-quarter release raised total revenue but did not mention those sub-guides; investors need to know if both still stand.
How much of Epidiolex's drop was wholesaler inventory?
Epidiolex sales fell 2.4% from a year ago, which Jazz blamed on prior-year rebate adjustments and lower wholesaler inventory build. Separating the one-off comparison from actual prescription volume growth will show if patient demand is still rising.
What are the clinical endpoints for the $754 million Actio drug?
Jazz booked a $754.2 million research write-off for Actio's ABS-1230 and plans to present initial patient data at a fourth-quarter medical meeting. Investors need to know how many patients will be shown and what seizure reduction clears the bar for registration.
Did Hikma give notice on the authorized generic oxybate deal?
High-sodium oxybate royalty revenue fell 27.4% from a year ago to $38.4 million, and Hikma's window to give termination notice opened on October 1, 2026. Clarifying whether either side gave notice will help size 2027 royalty revenue.